AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02764619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00184847
Drug: acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00184847
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00184847
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01317849
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.8mg
Trial: NCT01317849
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg
Trial: NCT01317849
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg
Trial: NCT01317849
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500ug
Trial: NCT01491958
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day +1, +3, and +6 and +11
Trial: NCT01979510
Drug: MK-0663B
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0663B once daily for 8 days.
Trial: NCT01979510
Drug: DOLOCAM PLUS®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOLOCAM PLUS® once daily for 8 days.
Trial: NCT01979510
Drug: Acetaminophen 500 mg
RxNorm normalized name: acetaminophen 500 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
Trial: NCT00775307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 400 mg/day (24 weeks)
Trial: NCT04359966
Drug: Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line therapy
Trial: NCT02652429
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two divided dosage
Trial: NCT00745030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 8 mg tablets
Trial: NCT01614457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
Trial: NCT02786537
Drug: SOF/LDV (sofosbuvir/ledipasvir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
Trial: NCT02786537
Drug: EBR/GZR (elbasvir/grazoprevir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
Trial: NCT04359953
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 2 x per day during 14 days
Trial: NCT00275379
Drug: ERB-041
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00643045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03016715
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04715750
Drug: [18F]-PI2620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
Trial: NCT00337636
Drug: Medication to suppress the immune system
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppression for 12 months post transplant
Trial: NCT00622934
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01845025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match formoterol one inhalation twice daily via dry powder inhaler
Trial: NCT04102501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
Trial: NCT00059475
Drug: Glycoprotein 100 (GP100): 209-217 (210M)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01837082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03127020
Drug: PQR309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
Trial: NCT00059475
Drug: Melanoma antigen recognized by T-cells (MART)-1: 27-35
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00059475
Drug: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00059475
Drug: melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02338362
Drug: Saline placebo inhaler
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline metered dose inhaler
Trial: NCT02426632
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
Trial: NCT02426632
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
Trial: NCT02426632
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
Trial: NCT02426632
Drug: Formulation M1
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Trial: NCT02426632
Drug: Formulation M2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Trial: NCT02426632
Drug: Formulation M3
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Trial: NCT02426632
Drug: Formulation N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Trial: NCT02426632
Drug: Formulation N2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Trial: NCT02426632
Drug: Formulation N3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Trial: NCT00524095
Drug: azithromycin and fluticasone
RxNorm normalized name: salmeterol and fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
Trial: NCT00524095
Drug: fluticasone and azithromycin
RxNorm normalized name: salmeterol and fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
Trial: NCT04281537
Drug: Enzyme Replacement Therapy (ERT)
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERT infusion every other week
Trial: NCT00811226
Drug: olmesartan medoxomile alone or combined with hydrochlorothiazide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
Trial: NCT01121406
Drug: Pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive PLD in a 4 week schedule
Trial: NCT01940718
Drug: Transdermal Androgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
Trial: NCT03827876
Drug: Enstilar 0.005%-0.064% Topical Foam
RxNorm normalized name: Enstilar 0.005%-0.064% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Trial: NCT01917825
Drug: MDT-15
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02610283
Drug: QPI-1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection
Trial: NCT01458769
Drug: Reyataz®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
Trial: NCT00659438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, once daily
Trial: NCT01633060
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 100 mg once daily
Trial: NCT01633060
Drug: BKM120 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 matching placebo, once daily
Trial: NCT04332549
Drug: PICS (Reconstitution Method 1 or 2)
RxNorm normalized name: Inova 8-2 Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
Trial: NCT03694522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion over approximately 30 minutes
Trial: NCT03694522
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours
Trial: NCT01533155
Drug: Nektar 118
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 25 mg tablet
Trial: NCT02085655
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT01164501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical to BI 10773 low dose
Trial: NCT01164501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical to BI 10773 high dose
Trial: NCT02515669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
Trial: NCT00957372
Drug: placebo (Part I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily placebo comparator
Trial: NCT01282814
Drug: Effexor® XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Extended-Release Capsule
Trial: NCT01367743
Drug: epinephrine perfusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
Trial: NCT02490540
Drug: Sufentanil SPI analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
Trial: NCT02490540
Drug: Sufentanil ANI analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
Trial: NCT02490540
Drug: Sufentanil anesthesiologist analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
Trial: NCT02904564
Drug: MMP with Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMP with saline infusion using tattoo device
Trial: NCT02100553
Drug: CE/BZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.45mg/BZA 20mg tablets, single dose on Day 5
Trial: NCT02100553
Drug: CE/BZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.45mg/BZA 20mg tablets, single dose
Trial: NCT02021422
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fluorouracil 2400 mg/m2 48 hours
Trial: NCT01134510
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS (comparable volume as intervention) twice weekly x 4wks
Trial: NCT00775372
Drug: Clarithromycin 250mg/5mL
RxNorm normalized name: CLARITHROMYCIN 250MG/5ML SUSP
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00377299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching active medication in all other physical aspects
Trial: NCT03984526
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
Trial: NCT04163783
Drug: [14C]-BGB-3111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,
Trial: NCT03667651
Drug: EpiCeram
RxNorm normalized name: EPICERAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
Trial: NCT01332435
Drug: 5ARI + AB
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
Trial: NCT02660580
Drug: MSB11022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
Trial: NCT00896519
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00896519
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03563248
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~* 5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~* Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~* Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~* Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle
Trial: NCT04745442
Drug: Best available treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will be treated with the best available treatment for COVID-19.
Trial: NCT03348683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
Trial: NCT03335124
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
Trial: NCT03335124
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
Trial: NCT03448835
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 850 mg /m2 4 cycles
Trial: NCT01483846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
Trial: NCT01717846
Drug: Group 1 or Orencia treated group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
Trial: NCT03937986
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacodynamic effects of placebo will be determined.
Trial: NCT02641899
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen 1000 mg on Day 1 and Day 27
Trial: NCT00345371
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01223911
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
Trial: NCT02857465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
Trial: NCT02857465
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
Trial: NCT00435539
Drug: Sham Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal sham injection
Trial: NCT02202603
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT02870673
Drug: SHINCORT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolone Acetonide (10mg/ml) 0.5 ml
Trial: NCT00159484
Drug: EPO906, celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
Trial: NCT02242279
Drug: BEA 2180 BR
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02085577
Drug: Usual daily opioids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients usual daily opioid consumption are administered during the study period
Trial: NCT02085577
Drug: Sufentanil 5 microgram/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.